Analysis of a separate dataset48 comparing matched pre- and on-treatment melanoma patient samples showed a significant overall increase in LAIR1 and HAVCR2 (TIM-3) expression when patients received anti-PD-1 therapy (Fig. 8c), consistent with our experimental models. This evidence concerns the gene HAVCR2 and melanoma.